|Bid||87.70 x 1800|
|Ask||87.71 x 4000|
|Day's Range||87.65 - 87.72|
|52 Week Range||8.80 - 87.72|
|Beta (5Y Monthly)||2.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 28, 2020 - Nov 02, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||75.62|
Moody's Investors Service ("Moody's") affirmed the ratings of Gilead Sciences, Inc. ("Gilead") including the A3 senior unsecured rating. At the same time, Moody's revised Gilead's outlook to negative.
Immunomedics' (IMMU) lead product candidate, Trodelvy, gets FDA orphan drug status for the treatment of adult and pediatric patients with glioblastoma.
NEW YORK, NY / ACCESSWIRE / October 12, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating:Cellular Biomedicine Group, Inc.